March 06, 2026 — Cambridge, Massachusetts, USA
A significant milestone has been reached in AI-driven pharmaceutical development as Insilico Medicine and TaiGen Biotechnology announced that ISM4808, an investigational therapy targeting chronic kidney disease (CKD)-related anemia, has successfully completed first human enrollment and dosing in a Phase I clinical trial. The milestone marks an important step forward for the AI-discovered drug candidate, which was originally developed using Insilico’s generative chemistry platform, Chemistry42, and later licensed to TaiGen for development and commercialization across the Greater China region. The progress highlights the growing impact of artificial intelligence technologies in accelerating pharmaceutical research and clinical development pipelines.
First Human Enrollment Signals Key Development Milestone
The successful first patient enrollment and dosing in the Phase I clinical trial represents a critical step in advancing ISM4808 from AI-enabled discovery into early-stage human testing. The clinical study is designed as a randomized, double-blind, placebo-controlled trial that includes both single-ascending-dose (SAD) and multiple-ascending-dose (MAD) cohorts. The primary goal of this trial is to evaluate the safety, tolerability, and pharmacokinetic profile of ISM4808 in healthy adult volunteers, providing essential data that will guide subsequent clinical development phases.
ISM4808 is a novel oral hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor, a therapeutic mechanism aimed at improving the management of anemia in patients suffering from chronic kidney disease. CKD is a growing global health concern, particularly in the Greater China region, where the prevalence of the disease continues to increase. Anemia remains one of the most common complications of CKD, affecting more than one in seven patients and significantly impacting quality of life and long-term health outcomes.
Unlike traditional Erythropoiesis-Stimulating Agents (ESAs), which typically require injections, ISM4808 works by stimulating the body’s natural production of erythropoietin (EPO) while simultaneously improving iron utilization. This mechanism may provide several advantages, including improved treatment convenience, enhanced iron efficiency, and the potential for a more favorable safety profile, positioning the candidate as a potential best-in-class oral therapy for CKD-related anemia.
Advertisement
Licensing Agreement Supports Clinical Development Strategy
The advancement of ISM4808 into clinical trials follows a strategic licensing agreement signed in December 2025 between Insilico Medicine and TaiGen Biotechnology. Under the terms of the agreement, TaiGen obtained exclusive rights to develop, commercialize, and sublicense the drug candidate across the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan. In return, Insilico Medicine is eligible to receive upfront payments, milestone payments tied to development and commercial achievements, and tiered royalties on future net sales. The total value of the partnership has been reported to potentially reach tens of millions of US dollars, underscoring the commercial potential of the program.
Since the partnership was established, TaiGen has rapidly advanced the program into clinical testing, demonstrating a highly efficient development process. According to company leadership, the first-subject enrollment was achieved within three months of licensing the program, highlighting TaiGen’s expertise in regulatory preparation and clinical trial execution. This rapid transition from licensing to clinical evaluation reflects a broader industry trend in which AI-enabled drug discovery platforms are significantly shortening the time required to move promising candidates from laboratory discovery to human trials.
AI-Enabled Drug Discovery Accelerates Therapeutic Innovation
The development of ISM4808 illustrates how artificial intelligence technologies are transforming the pharmaceutical R&D landscape. The candidate was initially identified and optimized using Chemistry42, Insilico Medicine’s AI-driven generative chemistry platform designed to accelerate molecular design and drug candidate selection. By leveraging advanced computational models, the platform can rapidly analyze complex chemical and biological datasets to identify promising therapeutic molecules with improved efficiency compared to traditional discovery methods.
Company scientists believe that this “AI-enabled discovery combined with specialized clinical development expertise” represents a powerful model for accelerating the delivery of innovative treatments to patients. In addition to ISM4808, Insilico Medicine is also advancing garutadustat, another drug candidate targeting the PHD pathway, for the treatment of inflammatory bowel disease, with its Phase II clinical trial initiating patient dosing earlier in 2026.
The progress of ISM4808 therefore highlights the growing role of AI-powered drug discovery platforms in modern pharmaceutical innovation, enabling researchers to identify promising therapeutic candidates faster, reduce development timelines, and address significant unmet medical needs such as CKD-related anemia. If clinical development continues successfully, ISM4808 could ultimately provide a safer and more convenient oral treatment option for millions of patients affected by chronic kidney disease and its complications worldwide.
z
Source: Insilico Medicine TaiGen press release
